Scholarlink

<p>Cytokine and oxylipin profiles in rat brain homogenates were characterized as an inflammatory response 6&#xa0;h after a single intracerebroventricular injection of LPS (19.3&#xa0;µg LPS/ventricle), serving as a model of the inflammatory process in trauma, stroke, and similar stroke-like conditions that cause acute reactions. The potential use of 4-methylumbelliferone (4-MU), an inhibitor of hyaluronic acid (HA) synthesis, clinically approved for the treatment of bile spasm, as an anti-inflammatory drug in the early stages of the brain’s response to a damaging stimulus was evaluated. i.c.v. injection of LPS induced proinflammatory genes expression (TNFα, IL-6 and IL-1β) and oxylipins synthesis. Simultaneous addition of 4-MU with LPS reduced LPS-induced TNFα, IL-1β, IL-6 release and reduced the increase in COX-derived metabolites—PGF<sub>2α</sub>, PGE<sub>2</sub>, 6-keto-PGF<sub>1α</sub>, TXB<sub>2</sub>, 12-HHT, and 15-HETE. LPS stimulated only the expression of HAS2, while the addition of 4-MU reduced the expression of LPS-stimulated HAS2, and induced the expression of HYAL1, but not HYAL2. Our results reveal significant changes in cytokines and oxylipins synthesis in the model of acute inflammation, and suggest that 4-MU can be viewed as a promising therapeutic agent in the early stages of neuroinflammation.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Inhibitor of hyaluronic acid synthesis 4-methylumbelliferone (4-MU) as a potential anti-inflammatory substance in acute neuroinflammation model in vivo

  • 期刊论文

  • 发表日期：

    2025年12月3日

查看全文
  • Dmitry V. Chistyakov,
  • Arina I. Nikolskaya,
  • Vladislav O. Gorbatenko,
  • Sergei V. Goriainov,
  • Denis N. Silachev,
  • Marina G. Sergeeva

摘要

Cytokine and oxylipin profiles in rat brain homogenates were characterized as an inflammatory response 6 h after a single intracerebroventricular injection of LPS (19.3 µg LPS/ventricle), serving as a model of the inflammatory process in trauma, stroke, and similar stroke-like conditions that cause acute reactions. The potential use of 4-methylumbelliferone (4-MU), an inhibitor of hyaluronic acid (HA) synthesis, clinically approved for the treatment of bile spasm, as an anti-inflammatory drug in the early stages of the brain’s response to a damaging stimulus was evaluated. i.c.v. injection of LPS induced proinflammatory genes expression (TNFα, IL-6 and IL-1β) and oxylipins synthesis. Simultaneous addition of 4-MU with LPS reduced LPS-induced TNFα, IL-1β, IL-6 release and reduced the increase in COX-derived metabolites—PGF2α, PGE2, 6-keto-PGF1α, TXB2, 12-HHT, and 15-HETE. LPS stimulated only the expression of HAS2, while the addition of 4-MU reduced the expression of LPS-stimulated HAS2, and induced the expression of HYAL1, but not HYAL2. Our results reveal significant changes in cytokines and oxylipins synthesis in the model of acute inflammation, and suggest that 4-MU can be viewed as a promising therapeutic agent in the early stages of neuroinflammation.